Gorbunova V A
Antibiot Khimioter. 1992 Mar;37(3):35-9.
Carminomycin is an original antitumor antibiotic from the anthracycline group isolated at the Institute of New Antibiotics (USSR) in 1973. Pharmacological investigation of carminomycin revealed its satisfactory absorption from the gastrointestinal tract which proved to be a distinguishing property of the antibiotic as compared to other anthracyclines such as adriamycin and rubomycin. The clinical trials of carminomycin showed that it was mainly active against soft tissue sarcoma and breast cancer, lymphosarcoma, neuroblastoma, Wilms' tumor and Ewing's sarcoma in children, as well as acute leukemia. Various regimens for the antibiotic administration were applied: short-term, single and long-term. Suppression of hemopoiesis was considered as a limiting toxic effect. By the data available carminomycin had lower cardiotoxicity as compared with rubomycin and adriamycin. Development of oral carminomycin is believed promising.
卡米诺霉素是一种源自蒽环类的新型抗肿瘤抗生素，于1973年在前苏联新抗生素研究所分离得到。对卡米诺霉素的药理学研究表明，它能从胃肠道得到良好吸收，这一特性使其有别于阿霉素和柔红霉素等其他蒽环类抗生素。卡米诺霉素的临床试验表明，它主要对软组织肉瘤、乳腺癌、淋巴肉瘤、神经母细胞瘤、儿童肾母细胞瘤和尤因肉瘤以及急性白血病有活性。采用了各种抗生素给药方案：短期、单次和长期。造血功能抑制被认为是一种限制性毒性作用。现有数据表明，与柔红霉素和阿霉素相比，卡米诺霉素的心脏毒性较低。口服卡米诺霉素的研发前景广阔。
